Angela C. Casbard
Cardiff, WLS, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Cediranib with weekly paclitaxel or olaparib versus weekly paclitaxel for advanced or recurrent endometrial cancer (COPELIA): a multicentre, open-label, randomised, phase 2 trial in the UK.
Journal: EClinicalMedicine
Published: April 09, 2026
Central data monitoring of clinical trials: A survey of the UK clinical research collaboration (UKCRC) registered clinical trial units.
Journal: Contemporary clinical trials
Published: October 30, 2025
A feasibility randomised trial of remotely delivered Video Interaction Guidance for parents of children with intellectual disability referred to specialist mental health services.
Journal: Pilot and feasibility studies
Published: June 05, 2025
Mapping the pathway and support offered to children with an intellectual disability referred to specialist mental health services in the UK.
Journal: BJPsych bulletin
Published: October 08, 2024
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: May 09, 2024
Remotely Delivered Video Interaction Guidance for Families of Children With an Intellectual Disability Referred to Specialist Mental Health Services: Protocol for a Feasibility Randomized Controlled Trial.
Journal: JMIR research protocols
Published: November 20, 2023
Watch Me Play!: protocol for a feasibility study of a remotely delivered intervention to promote mental health resilience for children (ages 0-8) across UK early years and children's services.
Journal: Pilot and feasibility studies
Published: September 19, 2023
HIDDEN2: Study protocol for the hospital deep vein thrombosis detection study in patients with cancer receiving palliative care.
Journal: BMJ open
Published: September 05, 2023
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
Journal: The Lancet. Oncology
Published: March 28, 2022
Last Updated: 09/26/2026